|
|
|
| The importance of multidisciplinary training in postgraduate training for glioma neurosurgeon |
| CHEN Baoshi ZHANG Zhong▲ |
| Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China |
|
|
|
|
Abstract Brain tumor is one of the ten most common tumors in China, glioma is the most common, accounting for 40%-60% of brain tumors. At the request of precision medicine, diagnosis and treatment of diseases is moving towards molecular diagnosis, individual and precise treatment of the direction of development, which puts a higher demand on the neurosurgical specialist. This article will present the importance in neurosurgery graduate students from the neurosurgery theory, the training of pathology and molecular pathology, sequencing and bioinformatics, radiochemotherapy, basic science research, neuroimaging, psychological intervention.
|
|
|
|
|
|
[1] 董楠，丁涟沐，孙晓阳.微侵袭神经导航系统在神经外科中的应用进展[J].现代医学，2013，41（12）：944-946.
[2] 黎平，闵苏，王萍，等.右美托咪定或丙泊酚复合瑞芬太尼用于功能神经外科术中唤醒的比较[J].临床麻醉学杂志，2011，27（8）：755-757.
[3] Jiang T，Mao Y，Ma W，et al. CGCG clinical practice guidelines for the management of adult diffuse gliomas [J]. Cancer Lett，2016，375（2）：263-273.
[4] Louis DN. Molecular pathology of malignant gliomas [J]. Annu Rev Pathol，2006，1：97-117.
[5] Chen B，Liang T，Yang P，et al. Classifying lower grade glioma cases according to whole genome gene expression [J]. Oncotarget，2016，7（45）：74031-74042.
[6] Bie L，Zhao G，Cheng P，et al. The accuracy of survival time prediction for patients with glioma is improved by measuring mitotic spindle checkpoint gene expression [J]. PLoS One，2011，6（10）：e25631.
[7] Yang P，Zhang W，Wang Y，et al. IDH mutation and MGMT promoter methylation in glioblastoma：results of a prospective registry [J]. Oncotarget，2015，6（38）：40 896-40 906.
[8] Wang Y，Wang X，Zhang J，et al. MicroRNAs involved in the EGFR/PTEN/AKT pathway in gliomas [J]. J Neurooncol，2012，106（2）：217-24.
[9] 李学真.神经外科硕士研究生临床带教方法的探讨[J].中国医药导报，2015，12（2）：121-124.
[10] Dullea A，Marignol L. MGMT testing allows for personalised therapy in the temozolomide era [J]. Tumour Biol，2016，37（1）：87-96.
[11] Zhao H， Wang S， Song C， et al. The prognostic value of MGMT promoter status by pyrosequencing assay for gliob?鄄lastoma patients' survival：a meta-analysis [J]. World J Surg Oncol，2016，14（1）：261.
[12] Kramar F， Minarik M， Benesova L， et al. IDH1/2 Mutation and MGMT promoter methylation-the relevant sur?鄄vival predictors in Czech patients with brain gliomas [J]. Folia Biol （Praha），2016，62（5）：194-202.
[13] Ballester LY，Huse JT，Tang G，et al. Molecular classification of adult diffuse fliomas： conflicting IDH1/IDH2，ATRX and 1p/19q results [J]. Hum Pathol，2017. DOI：10.1016/j.humpath.2017.05.005
[14] Hu X，Martinez-Ledesma E，Zheng S，et al. Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma [J]. Neuro Oncol，2017，19（6）：786-795.
[15] Patel SH，Poisson LM，Brat DJ，et al. T2-FLAIR mismatch，an imaging biomarker for IDH and 1p/19q status in lower grade gliomas：a TCGA/TCIA project [J]. Clin Cancer Res，2017，23（20）：6078-6085.
[16] Geng P，Zhao X，Ou J，et al. TERT genetic mutations as prognostic marker in glioma [J]. Mol Neurobiol，2017，54（5）：3665-3669.
[17] Karsy M，Guan J，Cohen AL，et al. New molecular considerations for glioma：IDH，ATRX，BRAF，TERT，H3 K27M [J]. Curr Neurol Neurosci Rep，2017，17（2）：19.
[18] Yang P，Cai J，Yan W，et al. Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas [J]. Neuro Oncol，2016，18（8）：1099-1108.
[19] Sun LH，Yang FQ，Zhang CB，et al. Overexpression of paxillin correlates with tumor progression and predicts poor survival in glioblastoma [J]. CNS Neurosci Ther，2017，23（1）：69-75.
[20] Wang H，Tao T，Yan W，et al. Upregulation of miR-181s reverses mesenchymal transition by targeting KPNA4 in glioblastoma [J]. Sci Rep，2015，5：13 072.
[21] Zhang W，Zhang J，Hoadley K，et al. miR-181d：a predictive glioblastoma biomarker that downregulates MGMT expression [J]. Neuro Oncol，2012，14（6）：712-719.
[22] Cheng W，Ren X，Cai J，et al. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients [J]. Oncotarget，2015，6（30）：29 285-29 295.
[23] Wang HY，Li JY，Liu X，et al. A three ion channel genes-based signature predicts prognosis of primary glioblastoma patients and reveals a chemotherapy sensitive subtype [J]. Oncotarget，2016，7（46）：74 895-74 903.
[24] Yang P，Zhang C，Cai J，et al. Radiation combined with temozolomide contraindicated for young adults diagnosed with anaplastic glioma [J]. Oncotarget，2016，7（48）：80 091-80 100.
[25] Li MY，Yang P，Liu YW，et al. Low c-Met expression levels are prognostic for and predict the benefits of temozolomide chemotherapy in malignant gliomas [J]. Sci Rep，2016，6：21 141.
[26] Yan W，Liu Y，Yang P，et al. MicroRNA profiling of Chinese primary glioblastoma reveals a temozolomide-chemoresistant subtype [J]. Oncotarget，2015，6（13）：11 676-11 682.
[27] Fan X，Wang Y，Liu Y，et al. Brain regions associated with telomerase reverse transcriptase promoter mutations in primary glioblastomas [J]. J Neurooncol，2016，128（3）：455-462. |
|
|
|
